NCT05526911View on ClinicalTrials.gov

A Phase 1, Drug-Drug Interaction Study of TBAJ-876 in Healthy Adults

PHASE1CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

June 30, 2022

Primary Completion Date

September 26, 2022

Study Completion Date

September 26, 2022

Conditions
Pulmonary DiseaseTuberculosis, PulmonaryTuberculosisMulti Drug Resistant TuberculosisDrug Sensitive TuberculosisDrug-resistant TuberculosisMycobacterium Tuberculosis Infection
Interventions
DRUG

TBAJ-876

"* Day 6 to Day 13: 200 mg TBAJ-876 oral suspension, fed~* Day 14 to Day 19: 165 mg TBAJ-876 oral suspension, fed~* Day 20 and Day 21: 200 mg TBAJ-876 oral suspension, fasting~* Day 22 to Day 24: 150 mg TBAJ-876 oral suspension, fed"

DRUG

Midazolam

Day 1 and Day 20: Midazolam oral syrup: 2 mg, fasted

DRUG

Digoxin

Day 2 and Day 21: Digoxin tablet: 0.25 mg, fasted

Trial Locations (1)

07410

TKL Research, Inc., Fair Lawn

All Listed Sponsors
lead

Global Alliance for TB Drug Development

OTHER